Stay updated on Pembrolizumab in Lymphoma Subtypes Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Lymphoma Subtypes Clinical Trial page.

Latest updates to the Pembrolizumab in Lymphoma Subtypes Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.5.4 was added to the page, replacing the previous Revision: v3.5.3. This reflects a new version of the page content without altering the study details.SummaryDifference0.0%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedThe page’s footer “Revision” value was updated from v3.5.2 to v3.5.3, indicating a minor platform/version change without altering study details.SummaryDifference0.0%

- Check43 days agoChange DetectedVersion bump from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check57 days agoChange Detected- Added inclusion criterion: B-cell lymphoma unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma.SummaryDifference0.0%

- Check72 days agoChange DetectedA new revision, v3.5.0, has been added; the previous revision, v3.4.3, has been removed.SummaryDifference0.0%

- Check79 days agoChange DetectedThe page now displays Revision: v3.4.3 and no longer shows Revision: v3.4.2.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab in Lymphoma Subtypes Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Lymphoma Subtypes Clinical Trial page.